BEIGENE (06160) opened more than 4% higher following its earnings release. At the time of writing, the stock was up 4.07% to HK$189.4, with a turnover of HK$41.31 million.

On May 6, BEIGENE reported its first-quarter 2026 financial results. Global total revenue reached approximately $1.513 billion, a 35% increase year-over-year. Adjusted operating profit was about $414 million, up 197% year-over-year, while adjusted net profit was approximately $375 million, a 175% increase. Net profit surged to approximately $227 million, a massive 178-fold increase compared to the prior year period. Free cash flow was approximately $161 million, representing a 14-fold increase.

Global sales of BRUKINSA® in the first quarter of 2026 totaled $1.1 billion, a 38% year-over-year increase. In the U.S. market specifically, BRUKINSA® sales reached $761 million, up 35%. Global sales of TEVIMBRA® (tislelizumab) for the quarter were $206 million, a 20% increase.

BEIGENE provided full-year 2026 total revenue guidance in the range of $6.3 billion to $6.5 billion. This projection reflects strong growth expectations driven by BRUKINSA®'s leading position in the U.S. market and its ongoing expansion in Europe and other key global markets. The company expects its gross margin to be at the high end of the 80% range, benefiting from product mix and improved production efficiency throughout 2026. The GAAP operating expense guidance includes anticipated investments to support commercial and research growth, aimed at achieving meaningful operating leverage.